Odyssey Therapeutics
↗Boston, MA, United States
Odyssey Therapeutics is a clinical-stage biopharmaceutical company transforming the standard of care for patients with autoimmune and inflammatory diseases. Founded in 2021 by serial biotech entrepreneur Gary Glick (previously CEO of Scorpion Therapeutics and founder of IFM Therapeutics), the company leverages a platform targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation. Odyssey's differentiated approach focuses on small molecule and protein therapeutics designed to precisely target disease drivers beyond current adaptive immune therapies. The company has rapidly advanced from stealth to Phase 2-ready status with a portfolio of internally discovered medicines addressing multiple autoimmune indications with significant unmet medical need.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology/Autoimmune Disease Therapeutics
SIZE & FINANCIALS
Employees:101-200
Revenue:Preclinical revenue; $3M collaboration revenue (12mo ended Sept 2024)
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series D
Total Raised:$700M
Investors:OrbiMed Advisors, SR One, General Catalyst, Foresite Capital, Catalio Capital Management, Woodline Partners LP, Lightspeed Ventures, TPG Life Sciences Innovations, Jeito Capital, Affinity Asset Advisors, Dimension Capital, Wedbush Healthcare Partners
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2a (OD-07656)
Modalities:Small molecule, Protein therapeutics
Active Trials:1
Trial Phases:Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Terray Therapeutics (strategic collaboration on transcription factor therapies), Vedolizumab (combination trial partner for OD-07656)
COMPETITION
Position:Challenger
Competitors:Gossamer Bio (GB004 for IBD), Protagonist Therapeutics, Seres Therapeutics, NovaBridge Biosciences, Jounce Therapeutics, Inovio Pharmaceuticals, Agenus, Rivus Pharmaceuticals +1 more
LEADERSHIP
Key Executives:
Gary D. Glick, Ph.D. - Founder, President & CEO
Jeffrey M. Leiden, M.D., Ph.D. - Board Chair
Jolie M. Siegel - Executive Vice President & General Counsel
Dennis Dean, Ph.D. - Executive Vice President, Head of Non-Clinical Development
Jeffrey Hermes, Ph.D. - Executive Vice President, Enabling Sciences
Scientific Founders:Gary D. Glick, Ph.D. (Founder & CEO)
Board Members:Jeffrey M. Leiden, M.D., Ph.D. (Chair), Gary D. Glick, Ph.D., Timothy P. Walbert (30+ years senior biopharma leadership; former Chairman, President & CEO of Horizon Therapeutics), Ian F. Smith (Chairman at Rivus Pharma, iVexSol; Executive Chairman at Solid Biosciences)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Odyssey Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Odyssey Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.